The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor

British Journal of Pharmacology

Volumn 124, Issue 5, 1998, Pages 889-896

  Gazi, L ^a   Bobirnac, I ^a   Danzeisen, M ^a   Schupbach E ^a   Bruinvels, A T ^a,b   Geisse, S ^a   Sommer, B ^a   Hoyer, D ^a   Tricklebank, M ^a   Schoeffter, P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

3H spiperone binding; Cyclic AMP inhibition; Dopamine D4 receptor; L 745,870; Schizophrenia; U 101958

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; CLOZAPINE; CYCLIC AMP; DOPAMINE 4 RECEPTOR; FORSKOLIN; N (1 BENZYL 4 PIPERIDINYL) N (3 ISOPROPOXY 2 PYRIDINYL) N METHYLAMINE; NEUROLEPTIC AGENT; QUINPIROLE; RACLOPRIDE; RADIOLIGAND; SPIPERONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL FREE SYSTEM; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL;

AMINOPYRIDINES; ANTIPSYCHOTIC AGENTS; CELL LINE; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FORSKOLIN; HUMANS; KIDNEY; PIPERIDINES; PYRIDINES; PYRROLES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECOMBINANT PROTEINS; SALICYLAMIDES; SPIPERONE;

EID: 7144264386     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701921     Document Type: Article

References (33)

1. 4 receptor variants. J. Neurochem., 65, 1157-1165.
2. 4 receptor repeat: analysis of different native and mutant forms of the human rat genes. Mol. Pharmacol., 46, 364-373.
3. BRISTOW, L.J., KRAMER, M.S., KULAGOWSKI, J., PATEL, S., RAGAN, C.I. & SEABROOK, G.R. (1997). Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol. Sci., 18, 186-188.
4. CHEN, C. & OKAYAMA, H. (1987). High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7, 2745-2752.
5. DELEAN, A., STADEL, J.M. & LEFKOWITZ, R.J. (1980). A ternary complex model explains the agonist specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem., 255, 7108-7117.
6. 4 receptor? Life Sci., 57, PL275-PL283.
7. 4 receptor agonists. Br. J. Pharmacol. Proc. Suppl., (in press).
8. GORMAN, C.M., GIES, D.R. & MCCRAY, G. (1990). Transient production of proteins using an Adenovirus transformed cell line. DNA Prot. Eng. Tech., 2, 3-10.
9. HARTMAN, D.S. & CIVELLI, O. (1997). Dopamine receptor diversity: molecular and pharmacological perspectives. In Progress in Drug Research, Vol. 4, ed. Jucker, E. 173-194. Basel: Birkhäuser.
10. KEBABIAN, J.W. & CALNE, D.B. (1979). Multiple receptors for dopamine. Nature, 277, 93-96.
11. 4 receptor. J. Med. Chem., 39, 1941-1942.
12. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol., 236, 483-486.
13. 4 (DRD4) gene. Hum. Mol. Genetics, 2, 767-773.
14. 4 receptor in human cerebral cortex and striatum. J. Neurochem., 66, 915-919.
15. MEADOR-WOODRUFF, J.H., DAMASK, B.S., WANG, J., HAROUTUNIAN, V., DAVIS, K.L. & WATSON, S.J. (1996). Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology, 15, 17-29.
16. MULLIS, K.B. & FALOONA, F.A. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol., 155, 335-350.
17. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci., 15, 2186-2191.
18. 4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J. Pharmacol. Exp. Ther., 282, 181-191.
19. 4 receptor. J. Pharmacol. Exp. Ther., 283, 636-647.
20. 3H]NGD 94-1. J. Pharmacol. Exp. Ther., 282, 1020-1027.
21. 4 receptors in the action and development of antipsychotic agents. Drugs. 51, 7-11.
22. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol., 281, R5-R6.
23. 3H]cAMP in cell monolayers, cell suspensions, and tissue slices. Methods Enzymol., 195, 22-28.
24. 4 receptor. Eur. J. Pharmacol., 322, 283-286.
25. 1A receptors: considerations on receptor effector coupling across systems. Neuropharmacology, 36, 429-437.
26. SEEMAN, P. (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1, 133-152.
27. 4. Neuropsychopharmacology, 7, 261-284.
28. 4 receptors elevated in schizophrenia. Nature, 365, 441-445.
29. SEEMAN, P. & NIZNIK, H.B. (1990). Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J., 4, 2737-2744.
30. SHAIKH, S., COLLIER, D., KERWIN, R.W., PILOWSKY, L.S., GILL, M., XU, W.M. & THORNTON, A. (1993). Dopamine D4 receptor subtypes and response to clozapine. Lancet, 341, 116.
31. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res., 681, 109-116.
32. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.
33. 4 receptor variants in the human population. Nature, 358, 149-152.